AN2 Therapeutics
ANTX
38 hedge funds and large institutions have $94.8M invested in AN2 Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
6% more funds holding
Funds holding: 36 → 38 (+2)
2% more capital invested
Capital invested by funds: $92.9M → $94.8M (+$1.82M)
0.84% less ownership
Funds ownership: 50.32% → 49.49% (-0.84%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$584K |
| 2 |
BlackRock
New York
|
+$425K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$243K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$139K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.25M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.02M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$227K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$52.1K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$12.3K |
ANTX Hedge Fund Activity: Q1 2023 in Review
38 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q1 2023, worth a combined $94.8M — up 2% from $92.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ANTX positions and 1 closed out — a net gain of 2 holders — while 20 added to existing stakes and 7 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $584K. The largest seller was Monashee Investment Management, cutting an estimated $2.25M.
- 38 institutional investors held AN2 Therapeutics (ANTX) as of Q1 2023, up from 36 in Q4 2022.
- Funds reported $94.8M of AN2 Therapeutics stock for Q1 2023, up 2% quarter-over-quarter.
- 3 funds opened new AN2 Therapeutics positions in Q1 2023 and 1 closed out, a net change of +2 holders.
- The largest AN2 Therapeutics buyer in Q1 2023 was Bridgeway Capital Management, an estimated $584K added.
- The largest AN2 Therapeutics seller in Q1 2023 was Monashee Investment Management, an estimated $2.25M sold.
Based on aggregated 13F filings for Q1 2023.